Rhenman & Partners Asset Management AB Purchases 190,000 Shares of Nurix Therapeutics, Inc. $NRIX

Rhenman & Partners Asset Management AB increased its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 54.7% during the fourth quarter, HoldingsChannel reports. The fund owned 537,500 shares of the company’s stock after acquiring an additional 190,000 shares during the quarter. Rhenman & Partners Asset Management AB’s holdings in Nurix Therapeutics were worth $10,196,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of NRIX. Larson Financial Group LLC increased its holdings in Nurix Therapeutics by 339.0% in the 4th quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock valued at $29,000 after buying an additional 1,190 shares during the period. Intesa Sanpaolo Wealth Management acquired a new stake in shares of Nurix Therapeutics in the 4th quarter valued at $31,000. Wexford Capital LP acquired a new stake in shares of Nurix Therapeutics in the 3rd quarter valued at $41,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Nurix Therapeutics by 66.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,926 shares of the company’s stock valued at $93,000 after purchasing an additional 1,970 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in Nurix Therapeutics by 118.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,413 shares of the company’s stock worth $73,000 after buying an additional 3,475 shares in the last quarter.

Nurix Therapeutics Trading Down 0.2%

Shares of NASDAQ NRIX opened at $16.95 on Friday. The stock has a 50-day moving average price of $16.42 and a two-hundred day moving average price of $16.92. Nurix Therapeutics, Inc. has a 12 month low of $8.19 and a 12 month high of $22.50. The company has a market cap of $1.75 billion, a price-to-earnings ratio of -5.36 and a beta of 1.86.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings results on Wednesday, April 8th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.03). The firm had revenue of $6.25 million for the quarter, compared to the consensus estimate of $14.25 million. Nurix Therapeutics had a negative return on equity of 64.21% and a negative net margin of 411.37%. On average, sell-side analysts predict that Nurix Therapeutics, Inc. will post -2.88 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. BTIG Research upped their price target on shares of Nurix Therapeutics from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday. Wells Fargo & Company cut Nurix Therapeutics from an “overweight” rating to a “hold” rating and lowered their price target for the company from $28.00 to $25.00 in a research note on Monday, June 8th. Jefferies Financial Group increased their target price on Nurix Therapeutics from $41.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, June 8th. HC Wainwright reissued a “buy” rating and set a $32.00 target price on shares of Nurix Therapeutics in a research note on Wednesday. Finally, Needham & Company LLC upped their price target on Nurix Therapeutics from $26.00 to $34.00 and gave the stock a “buy” rating in a research report on Monday, June 8th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Nurix Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $32.14.

Insider Activity

In other news, CFO Houte Hans Van sold 14,055 shares of the business’s stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $16.60, for a total transaction of $233,313.00. Following the sale, the chief financial officer directly owned 37,592 shares in the company, valued at approximately $624,027.20. The trade was a 27.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 3,214 shares of the firm’s stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $16.65, for a total value of $53,513.10. Following the transaction, the insider owned 120,399 shares of the company’s stock, valued at $2,004,643.35. This trade represents a 2.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 19,657 shares of company stock worth $326,586. Company insiders own 6.70% of the company’s stock.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.